Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.39 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18823197 | 0.98 | FAP (0.47) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL19708797 | 0.98 | FAP (0.47) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL18823198 | 0.98 | FAP (0.47) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL23268956 | 0.98 | FAP (0.47) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL18909001 | 0.98 | FAP (0.47) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL24068331 | 0.98 | FAP (0.47) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL18823482 | 0.97 | FAP (0.46) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL19750495 | 0.97 | FAP (0.46) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL19387405 | 0.97 | FAP (0.46) | FAPSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL26412946 | 0.93 | FAP (0.47) | FAPSIRT2SIRT1SIRT3SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045480-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200362054-A1 | TRISPECIFIC BINDING MOLECULES AGAINST TUMOR-ASSOCIATED ANTIGENTS AND USE THEREOF | NOVARTIS AG (CH) | 2020-11-19 | — | — | US | disclosed |
| US-20200215200-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2020-07-09 | — | — | US | disclosed |
| US-20190105328-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2019-04-11 | — | — | US | disclosed |
| US-20190099431-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2019-04-04 | — | — | US | disclosed |
| US-10011657-B2 | Anti-CS1 antibodies and antibody drug conjugates | ABBVIE BIOTHERAPEUTICS INC. (US) | 2018-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11045480-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | LRRC59, LRRC47, HACD3 | FAP 4569/4885SIRT2 4097/4885SIRT1 4465/4885 |
| US-20200215200-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | FAP 3032/4885SIRT2 4689/4885SIRT1 4857/4885 |
| US-20190099431-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | FAP 4569/4885SIRT2 4097/4885SIRT1 4465/4885 |
| US-20190105328-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | FAP 4569/4885SIRT2 4097/4885SIRT1 4465/4885 |
| US-20200362054-A1 | TRISPECIFIC BINDING MOLECULES AGAINST TUMOR-ASSOCIATED ANTIGENTS AND USE THEREOF | CD2, CD2BP2, CD22 | FAP 550/4885SIRT2 4865/4885SIRT1 4876/4885 |
| US-10011657-B2 | Anti-CS1 antibodies and antibody drug conjugates | CD47, CSGALNACT1, CSE1L | FAP 4279/4885SIRT2 3559/4885SIRT1 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.